{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:03:56Z","timestamp":1774976636686,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-026-00626-y","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:15:20Z","timestamp":1772097320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-course prednisone and methotrexate in a cohort of patients with polymyalgia rheumatica: a potential therapeutic approach"],"prefix":"10.1186","volume":"10","author":[{"given":"Edoardo","family":"Conticini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Truscelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Grazzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Falsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Cartocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"626_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard-2022-223429","volume":"83","author":"C Dejaco","year":"2023","unstructured":"Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2023;83:48\u201357. https:\/\/doi.org\/10.1136\/ard-2022-223429.","journal-title":"Ann Rheum Dis"},{"key":"626_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ACR.25216","volume":"76","author":"SE Sattui","year":"2024","unstructured":"Sattui SE, Xie F, Wan Z, Clinton C, Domsic RT, Curtis JR. Treatment of polymyalgia rheumatica by rheumatology providers: analysis from the American college of rheumatology RISE registry. Arthritis Care Res (Hoboken). 2024;76:259\u201364. https:\/\/doi.org\/10.1002\/ACR.25216.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"626_CR3","doi-asserted-by":"publisher","unstructured":"Muller S, Hider SL, Singh Sokhal B, Lawton SA, Helliwell T, Mallen CD. Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR cohort study. Rheumatol Adv Pract. 2022;6. https:\/\/doi.org\/10.1093\/RAP\/RKAC034.","DOI":"10.1093\/RAP\/RKAC034"},{"key":"626_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/ANNRHEUMDIS-2021-221126","volume":"81","author":"M Bonelli","year":"2022","unstructured":"Bonelli M, Radner H, Kerschbaumer A, Mrak D, Durechova M, Stieger J, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial. Ann Rheum Dis. 2022;81:838\u201344. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2021-221126.","journal-title":"Ann Rheum Dis"},{"key":"626_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMOA2303452","volume":"389","author":"RF Spiera","year":"2023","unstructured":"Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med. 2023;389:1263\u201372. https:\/\/doi.org\/10.1056\/NEJMOA2303452.","journal-title":"N Engl J Med"},{"key":"626_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/JAMA.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, et al. Effect of Tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: A randomized clinical trial. JAMA. 2022;328:1053\u201362. https:\/\/doi.org\/10.1001\/JAMA.2022.15459.","journal-title":"JAMA"},{"key":"626_CR7","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/S00296-012-2580-4","volume":"33","author":"JH Lee","year":"2013","unstructured":"Lee JH, Choi ST, Kim JS, Yoon BY, Kwok SK, Kim HS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int. 2013;33:1475\u201380. https:\/\/doi.org\/10.1007\/S00296-012-2580-4.","journal-title":"Rheumatol Int"},{"key":"626_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/ARD.55.4.218","volume":"55","author":"MJ Van Der Veen","year":"1996","unstructured":"Van Der Veen MJ, Dinant HJ, Van Booma-Frankfort C, Van Albada-Kuipers GA, Bijlsma JWJ. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996;55:218\u201323. https:\/\/doi.org\/10.1136\/ARD.55.4.218.","journal-title":"Ann Rheum Dis"},{"key":"626_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/HEALTHCARE13111226","volume":"13","author":"P Falsetti","year":"2025","unstructured":"Falsetti P, Manzo C, Isetta M, Placido F, Castagna A, Natale M, et al. Are there definite disease subsets in polymyalgia rheumatica? Suggestions from a narrative review. Healthcare. 2025;13:1226. https:\/\/doi.org\/10.3390\/HEALTHCARE13111226.","journal-title":"Healthcare"},{"key":"626_CR10","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/S11739-023-03373-X\/FIGURES\/2","volume":"18","author":"E Conticini","year":"2023","unstructured":"Conticini E, Falsetti P, d\u2019Alessandro M, Al Khayyat SG, Grazzini S, Baldi C, et al. Clinical, laboratory and ultrasonographic findings at baseline predict long-term outcome of polymyalgia rheumatica: a multicentric retrospective study: polymyalgia rheumatica predicted by ultrasonographic findings polymyalgia rheumatica outcome predicted early by ultrasound. Intern Emerg Med. 2023;18:1929\u201339. https:\/\/doi.org\/10.1007\/S11739-023-03373-X\/FIGURES\/2.","journal-title":"Intern Emerg Med"},{"key":"626_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/ANNRHEUMDIS-2011-200329","volume":"71","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: A European league against Rheumatism\/American college of rheumatology collaborative initiative. Ann Rheum Dis. 2012;71:484\u201392. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2011-200329.","journal-title":"Ann Rheum Dis"},{"key":"626_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/ART.34356","volume":"64","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: A European league against Rheumatism\/American college of rheumatology collaborative initiative. Arthritis Rheum. 2012;64:943\u201354. https:\/\/doi.org\/10.1002\/ART.34356.","journal-title":"Arthritis Rheum"},{"key":"626_CR13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/ANNRHEUMDIS-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European league against Rheumatism\/American college of rheumatology collaborative initiative. Ann Rheum Dis. 2015;74:1799\u2013807. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2015-207492.","journal-title":"Ann Rheum Dis"},{"key":"626_CR14","first-page":"104","volume":"37","author":"F Laskou","year":"2019","unstructured":"Laskou F, Coath F, Mackie SL, Banerjee S, Aung T, Dasgupta B. A probability score to aid the diagnosis of suspected giant cell arteritis. Clin Exp Rheumatol. 2019;37:104\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"626_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/ard-2022-223367","volume":"82","author":"C Dejaco","year":"2023","unstructured":"Dejaco C, Ponte C, Monti S, Rozza D, Scir\u00e8 CA, Terslev L, et al. The provisional OMERACT ultrasonography score for giant cell arteritis. Ann Rheum Dis. 2023;82:556\u201364. https:\/\/doi.org\/10.1136\/ard-2022-223367.","journal-title":"Ann Rheum Dis"},{"key":"626_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/REUMATISMO.2020.1268","volume":"72","author":"N Ughi","year":"2020","unstructured":"Ughi N, Sebastiani GD, Gerli R, Salvaran C, Parisi S, Ariani A, et al. The Italian society of rheumatology clinical practice guidelines for the management of polymyalgia rheumatic. Reumatismo. 2020;72:1\u201315. https:\/\/doi.org\/10.4081\/REUMATISMO.2020.1268.","journal-title":"Reumatismo"},{"key":"626_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al. Prednisone plus methotrexate for polymyalgia rheumatica: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141:493\u2013500. https:\/\/doi.org\/10.7326\/0003-4819-141-7-200410050-00005.","journal-title":"Ann Intern Med"},{"key":"626_CR18","first-page":"624","volume":"23","author":"G Ferraccioli","year":"1996","unstructured":"Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996;23:624\u20138.","journal-title":"J Rheumatol"},{"key":"626_CR19","doi-asserted-by":"publisher","unstructured":"Dubost JJ, Pereira B, Fan A, Soubrier M. What is the starting dose of steroid prescribed by rheumatologist in the management of polymyalgia rheumatica? Ann Rheum Dis. 2021;80. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2019-216050.","DOI":"10.1136\/ANNRHEUMDIS-2019-216050"},{"key":"626_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3899\/JRHEUM.110851","volume":"39","author":"M Mazzantini","year":"2012","unstructured":"Mazzantini M, Torre C, Miccoli M, Baggiani A, Talarico R, Bombardieri S, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: A retrospective study. J Rheumatol. 2012;39:552\u20137. https:\/\/doi.org\/10.3899\/JRHEUM.110851.","journal-title":"J Rheumatol"},{"key":"626_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/S10067-021-05819-Z","volume":"41","author":"A Floris","year":"2022","unstructured":"Floris A, Piga M, Chessa E, Congia M, Erre GL, Angioni MM, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. 2022;41:19\u201331. https:\/\/doi.org\/10.1007\/S10067-021-05819-Z.","journal-title":"Clin Rheumatol"},{"key":"626_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/RHEUMATOLOGY\/KEAD471","volume":"63","author":"E Hysa","year":"2024","unstructured":"Hysa E, Bond M, Ehlers L, Camellino D, Falzon L, Dejaco C, et al. Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review. Rheumatology (Oxford). 2024;63:285\u201397. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAD471.","journal-title":"Rheumatology (Oxford)"},{"key":"626_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/ARD-2023-224768","volume":"83","author":"E De Miguel","year":"2023","unstructured":"De Miguel E, Karalilova R, MacChioni P, Ponte C, Conticini E, Cowley S, et al. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica. Ann Rheum Dis. 2023;83:335\u201341. https:\/\/doi.org\/10.1136\/ARD-2023-224768.","journal-title":"Ann Rheum Dis"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00626-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00626-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00626-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:59:07Z","timestamp":1774972747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-026-00626-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00626-y","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with Helsinki declaration and further amendments and was approved by local ethical committee \u201cComitato Etico Area Vasta sud-est\u201d (RHELABUS, 22271). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}